Groupama Asset Managment Lowers Position in Jazz Pharmaceuticals PLC $JAZZ

Groupama Asset Managment decreased its holdings in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 70.5% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 2,576 shares of the specialty pharmaceutical company’s stock after selling 6,142 shares during the period. Groupama Asset Managment’s holdings in Jazz Pharmaceuticals were worth $340,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Farther Finance Advisors LLC grew its stake in Jazz Pharmaceuticals by 754.8% in the 3rd quarter. Farther Finance Advisors LLC now owns 265 shares of the specialty pharmaceutical company’s stock worth $35,000 after buying an additional 234 shares in the last quarter. Danske Bank A S purchased a new stake in shares of Jazz Pharmaceuticals during the 3rd quarter valued at $40,000. Quent Capital LLC purchased a new stake in shares of Jazz Pharmaceuticals during the 3rd quarter valued at $44,000. Caitong International Asset Management Co. Ltd lifted its holdings in shares of Jazz Pharmaceuticals by 1,383.3% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 356 shares of the specialty pharmaceutical company’s stock worth $47,000 after acquiring an additional 332 shares during the last quarter. Finally, Geneos Wealth Management Inc. lifted its holdings in shares of Jazz Pharmaceuticals by 57.6% during the 1st quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock worth $47,000 after acquiring an additional 137 shares during the last quarter. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the company. Barclays reissued an “overweight” rating and issued a $224.00 target price on shares of Jazz Pharmaceuticals in a research note on Monday, March 9th. Truist Financial upped their price objective on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the stock a “buy” rating in a report on Monday, January 12th. Piper Sandler increased their price objective on Jazz Pharmaceuticals from $219.00 to $232.00 and gave the company an “overweight” rating in a research report on Thursday. TD Cowen reissued a “buy” rating on shares of Jazz Pharmaceuticals in a report on Thursday, January 29th. Finally, Needham & Company LLC upped their target price on Jazz Pharmaceuticals from $210.00 to $235.00 and gave the stock a “buy” rating in a research note on Monday, January 12th. Thirteen research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Jazz Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $215.38.

Jazz Pharmaceuticals Trading Down 0.6%

Shares of JAZZ stock opened at $180.62 on Friday. The business has a 50-day moving average of $173.81 and a 200 day moving average of $158.09. The company has a debt-to-equity ratio of 1.00, a current ratio of 1.86 and a quick ratio of 1.67. Jazz Pharmaceuticals PLC has a 1-year low of $95.49 and a 1-year high of $198.00. The stock has a market capitalization of $11.12 billion, a PE ratio of -30.25, a P/E/G ratio of 0.33 and a beta of 0.22.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings results on Tuesday, February 24th. The specialty pharmaceutical company reported $6.64 EPS for the quarter, topping analysts’ consensus estimates of $6.49 by $0.15. Jazz Pharmaceuticals had a positive return on equity of 6.87% and a negative net margin of 8.35%.The business had revenue of $1.20 billion for the quarter, compared to analysts’ expectations of $1.17 billion. During the same period in the previous year, the firm earned $6.51 EPS. The business’s quarterly revenue was up 8.1% on a year-over-year basis. As a group, sell-side analysts anticipate that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current year.

Insider Activity

In other Jazz Pharmaceuticals news, SVP Mary Elizabeth Henderson sold 5,343 shares of the stock in a transaction on Thursday, February 26th. The shares were sold at an average price of $194.49, for a total transaction of $1,039,160.07. Following the completion of the sale, the senior vice president owned 28,728 shares of the company’s stock, valued at $5,587,308.72. This represents a 15.68% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CAO Patricia Carr sold 1,287 shares of the firm’s stock in a transaction on Monday, March 9th. The stock was sold at an average price of $182.94, for a total transaction of $235,443.78. Following the completion of the sale, the chief accounting officer directly owned 6,512 shares in the company, valued at approximately $1,191,305.28. This trade represents a 16.50% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 68,015 shares of company stock valued at $13,037,486 in the last three months. Corporate insiders own 4.30% of the company’s stock.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.